QIAGEN Acquires Parse Biosciences for $225 Million to Expand Single-Cell Analysis Capabilities
Key Insights
QIAGEN announced the acquisition of Parse Biosciences (search) for $225 million upfront plus potential milestone payments, expanding its portfolio into the rapidly growing single-cell sequencing market.
Parse's Evercode (search) platform enables instrument-free analysis of millions to billions of cells, addressing the increasing demand for large-scale datasets in AI-driven drug discovery.
The acquisition positions QIAGEN to capitalize on the single-cell market expected to grow from $1.2 billion in 2024 to $2.1 billion by 2029, driven by pharmaceutical companies' need for massive cellular datasets.
QIAGEN announced it has entered into a definitive agreement to fully acquire Parse Biosciences (search), a leading provider of scalable, instrument-free solutions for single-cell research, for approximately $225 million in cash with additional potential milestone payments of up to $55 million. The transaction is expected to be completed in December 2025.
The acquisition significantly expands QIAGEN's Sample technologies portfolio into the fast-growing single-cell sequencing market, which is expected to grow from about $1.2 billion in 2024 to $2.1 billion by 2029, reflecting annual growth of about 10%. This expansion is being driven by AI-based drug discovery as pharmaceutical and biotechnology companies generate large-scale cellular datasets to train predictive models of biology.
Strategic Positioning in AI-Driven Biology
Parse Biosciences (search) brings its proprietary Evercode (search) combinatorial barcoding platform, which is highly differentiated by enabling large-scale projects to analyze millions and billions of cells—a capability lacking in other single-cell offerings. The company's technologies are used in more than 3,000 labs across over 40 countries, including all of the top 50 research institutions and top 10 pharmaceutical companies.
"The addition of the Parse team to QIAGEN will significantly strengthen our offerings in one of the most dynamic areas of life science," said Thierry Bernard, CEO of QIAGEN. "Single-cell analysis is the key to understanding health and disease at a mechanistic level. By combining Parse with our Sample technologies portfolio and QDI bioinformatics offering, we can provide researchers with the tools to generate the massive datasets required to build predictive virtual cell models that fuel AI-based drug discovery."
Technology Advantages and Market Impact
Parse's technology is designed to profile more cells in less time, addressing the increasing demand among customers for massive-scale projects, particularly in pharmaceutical and academic research. Key advantages of the platform include its instrument-free approach, which allows for rapid customer adoption and use in any laboratory, creating a major differentiator in scalability.
The company has pioneered high-throughput single-cell analysis, highlighted by the Tahoe-100M dataset—the largest publicly available single-cell dataset to date comprising more than 100 million single-cell transcriptomes. Parse's latest offering, GigaLab (search), provides a high-throughput service with a capacity of 2.5 billion cells per year, supporting multi-million cell projects used in drug and target screens across therapeutic areas such as oncology, immunology and neurology.
Financial Projections and Integration
For full-year 2026, Parse is expected to contribute approximately $40 million in sales to QIAGEN, representing approximately two percentage points of growth, with sales expected to increase at a strong double-digit rate in subsequent years. The transaction is expected to be dilutive to adjusted earnings per share by approximately $0.04 in 2026 and accretive beginning in 2028.
Parse's scalable chemistry is also expected to accelerate growth in the QIAGEN Digital Insights (search) bioinformatics business, enabling customers to generate, process and interpret AI-driven single-cell data more efficiently and at much greater scale, from the first sample to actionable insights.
"Parse was founded to make single-cell sequencing accessible to any lab," said Alex Rosenberg, PhD, CEO and co-founder of Parse Biosciences (search). "As our team joins QIAGEN, we want to accelerate that mission and extend the reach of our technology to more customers around the world. QIAGEN's strong commitment to Sample technologies and its global infrastructure make it an ideal partner for our next stage of growth."
The transaction, which is subject to clearance under the U.S. Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions, strengthens Parse's intellectual property position through its exclusive license to 36 granted University of Washington patents on split-pool combinatorial barcoding for all fields, providing broad protection for its proprietary technology.